185 related articles for article (PubMed ID: 37418076)
1. Analysis of the genomic landscape of primary central nervous system lymphoma using whole-genome sequencing in Chinese patients.
Yuan X; Yu T; Zhao J; Jiang H; Hao Y; Lei W; Liang Y; Li B; Qian W
Front Med; 2023 Oct; 17(5):889-906. PubMed ID: 37418076
[TBL] [Abstract][Full Text] [Related]
2. Analysis of Genomic Alteration in Primary Central Nervous System Lymphoma and the Expression of Some Related Genes.
Zhou Y; Liu W; Xu Z; Zhu H; Xiao D; Su W; Zeng R; Feng Y; Duan Y; Zhou J; Zhong M
Neoplasia; 2018 Oct; 20(10):1059-1069. PubMed ID: 30227305
[TBL] [Abstract][Full Text] [Related]
3. The PI3K/AKT/mTOR signaling pathway is aberrantly activated in primary central nervous system lymphoma and correlated with a poor prognosis.
Zhang X; Wu Y; Sun X; Cui Q; Bai X; Dong G; Gao Z; Wang Y; Gao C; Sun S; Ji N; Liu Y
BMC Cancer; 2022 Feb; 22(1):190. PubMed ID: 35184749
[TBL] [Abstract][Full Text] [Related]
4. Whole-Exome Sequencing Revealed the Mutational Profiles of Primary Central Nervous System Lymphoma.
Zhang R; Wei B; Hu Y; Lv W; Adilai A; Yang F; Zhang J; Cheng G
Clin Lymphoma Myeloma Leuk; 2023 Apr; 23(4):291-302. PubMed ID: 36725383
[TBL] [Abstract][Full Text] [Related]
5. Whole-Genome/Exome Sequencing Uncovers Mutations and Copy Number Variations in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.
Zhu Q; Wang J; Zhang W; Zhu W; Wu Z; Chen Y; Chen M; Zheng L; Tang J; Zhang S; Wang D; Wang X; Chen G
Front Genet; 2022; 13():878618. PubMed ID: 35646048
[No Abstract] [Full Text] [Related]
6. Genomic profiling combined with gene expression profiling in primary central nervous system lymphoma.
Sung CO; Kim SC; Karnan S; Karube K; Shin HJ; Nam DH; Suh YL; Kim SH; Kim JY; Kim SJ; Kim WS; Seto M; Ko YH
Blood; 2011 Jan; 117(4):1291-300. PubMed ID: 21088137
[TBL] [Abstract][Full Text] [Related]
7. The genomic and transcriptional landscape of primary central nervous system lymphoma.
Radke J; Ishaque N; Koll R; Gu Z; Schumann E; Sieverling L; Uhrig S; Hübschmann D; Toprak UH; López C; Hostench XP; Borgoni S; Juraeva D; Pritsch F; Paramasivam N; Balasubramanian GP; Schlesner M; Sahay S; Weniger M; Pehl D; Radbruch H; Osterloh A; Korfel A; Misch M; Onken J; Faust K; Vajkoczy P; Moskopp D; Wang Y; Jödicke A; Trümper L; Anagnostopoulos I; Lenze D; Küppers R; Hummel M; Schmitt CA; Wiestler OD; Wolf S; Unterberg A; Eils R; Herold-Mende C; Brors B; ; Siebert R; Wiemann S; Heppner FL
Nat Commun; 2022 May; 13(1):2558. PubMed ID: 35538064
[TBL] [Abstract][Full Text] [Related]
8. Characterization of genomic alterations in primary central nervous system lymphomas.
Zorofchian S; El-Achi H; Yan Y; Esquenazi Y; Ballester LY
J Neurooncol; 2018 Dec; 140(3):509-517. PubMed ID: 30171453
[TBL] [Abstract][Full Text] [Related]
9. Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas.
Braggio E; Van Wier S; Ojha J; McPhail E; Asmann YW; Egan J; da Silva JA; Schiff D; Lopes MB; Decker PA; Valdez R; Tibes R; Eckloff B; Witzig TE; Stewart AK; Fonseca R; O'Neill BP
Clin Cancer Res; 2015 Sep; 21(17):3986-94. PubMed ID: 25991819
[TBL] [Abstract][Full Text] [Related]
10.
Nayyar N; White MD; Gill CM; Lastrapes M; Bertalan M; Kaplan A; D'Andrea MR; Bihun I; Kaneb A; Dietrich J; Ferry JA; Martinez-Lage M; Giobbie-Hurder A; Borger DR; Rodriguez FJ; Frosch MP; Batchelor E; Hoang K; Kuter B; Fortin S; Holdhoff M; Cahill DP; Carter S; Brastianos PK; Batchelor TT
Blood Adv; 2019 Feb; 3(3):375-383. PubMed ID: 30723112
[TBL] [Abstract][Full Text] [Related]
11. Diversity of genetic alterations of primary central nervous system lymphoma in Hispanic versus non-Hispanic patients.
Barakat M; Albitar M; Whitney R; Abdulhaq H
Cancer Treat Res Commun; 2021; 27():100310. PubMed ID: 33581493
[TBL] [Abstract][Full Text] [Related]
12. CD79B Y196 mutation is a potent predictive marker for favorable response to R-MPV in primary central nervous system lymphoma.
Yamaguchi J; Ohka F; Lushun C; Motomura K; Aoki K; Takeuchi K; Nagata Y; Ito S; Mizutani N; Ohno M; Suzaki N; Takasu S; Seki Y; Kano T; Wakabayashi K; Oyama H; Kurahashi S; Tanahashi K; Hirano M; Shimizu H; Kitano Y; Maeda S; Yamazaki S; Wakabayashi T; Kondo Y; Natsume A; Saito R
Cancer Med; 2023 Mar; 12(6):7116-7126. PubMed ID: 36478416
[TBL] [Abstract][Full Text] [Related]
13. Primary central nervous system lymphoma in China: a single-center retrospective analysis of 167 cases.
Yuan XG; Huang YR; Yu T; Xu Y; Liang Y; Zhang XH; Sun CR; Zhao XY
Ann Hematol; 2020 Jan; 99(1):93-104. PubMed ID: 31758262
[TBL] [Abstract][Full Text] [Related]
14. TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy.
Munch-Petersen HD; Asmar F; Dimopoulos K; Areškevičiūtė A; Brown P; Girkov MS; Pedersen A; Sjö LD; Heegaard S; Broholm H; Kristensen LS; Ralfkiaer E; Grønbæk K
Acta Neuropathol Commun; 2016 Apr; 4():40. PubMed ID: 27101868
[TBL] [Abstract][Full Text] [Related]
15. The outcome of ibrutinib-based regimens in relapsed/refractory central nervous system lymphoma and the potential impact of genomic variants.
Wang S; Zhu Y; Qian X; Ding T; Yuan Y; Li Y; Wu H; Chen T
Adv Clin Exp Med; 2023 Aug; 32(8):855-863. PubMed ID: 36881367
[TBL] [Abstract][Full Text] [Related]
16. The role of comorbidity indices and histochemical markers in surgically resected and non-resected primary central nervous system lymphoma.
Wong CE; Liao WA; Chang Y; Lee PH; Huang CC; Chang KC; Lee JS
Clin Exp Med; 2023 Nov; 23(7):3799-3807. PubMed ID: 37491648
[TBL] [Abstract][Full Text] [Related]
17. Role of Rituximab in Treatment of Patients With Primary Central Nervous System Lymphoma (PCNSL): A Systematic Review and Meta-Analysis.
Zhang Y; Liu Z; Gao C; Bian H; Ma Y; Jing F; Zhao X
Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):733-741. PubMed ID: 37453867
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological analysis and specific discriminating markers of interleukin detection in cerebrospinal fluid with primary central nervous system lymphoma: results from a retrospective study.
Li J; Tang X; Luo X; Liu L; Li D; Yang L
Ann Hematol; 2023 Aug; 102(8):2153-2163. PubMed ID: 37289220
[TBL] [Abstract][Full Text] [Related]
19. Reciprocal expression of the immune response genes CXCR3 and IFI44L as module hubs are associated with patient survivals in primary central nervous system lymphoma.
Takashima Y; Hamano M; Yoshii K; Hayano A; Fukai J; Iwadate Y; Kajiwara K; Hondoh H; Yamanaka R
Int J Clin Oncol; 2023 Mar; 28(3):468-481. PubMed ID: 36607476
[TBL] [Abstract][Full Text] [Related]
20. Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral Biopsy.
Montesinos-Rongen M; Brunn A; Tuchscherer A; Borchmann P; Schorb E; Kasenda B; Altmüller J; Illerhaus G; Ruge MI; Maarouf M; Büttner R; Hansmann ML; Hallek M; Prinz M; Siebert R; Deckert M
J Mol Diagn; 2020 Oct; 22(10):1300-1307. PubMed ID: 32745612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
